NO20081100L - Pharmaceutical dosage forms and compositions - Google Patents
Pharmaceutical dosage forms and compositionsInfo
- Publication number
- NO20081100L NO20081100L NO20081100A NO20081100A NO20081100L NO 20081100 L NO20081100 L NO 20081100L NO 20081100 A NO20081100 A NO 20081100A NO 20081100 A NO20081100 A NO 20081100A NO 20081100 L NO20081100 L NO 20081100L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- dosage forms
- pharmaceutical dosage
- methods
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Oppfinnelsen angår for eksempel nye formuleringer og metoder for levering av 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioksin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamid, farmasøytisk akseptable salter derav, strukturelt beslektede forbindelser og/eller metabolitter; så vel som anvendelse av disse formuleringer og metoder for behandling av sykdom.The invention relates, for example, to new formulations and methods for the delivery of 4-cyano-N - {(2R) -2- [4- (2,3-dihydro-benzo [1,4] dioxin-5-yl) -piperazine-1 -yl] -propyl} -N-pyridin-2-yl-benzamide, pharmaceutically acceptable salts thereof, structurally related compounds and / or metabolites; as well as the application of these formulations and methods for the treatment of disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71541705P | 2005-09-09 | 2005-09-09 | |
PCT/US2006/034813 WO2007030589A2 (en) | 2005-09-09 | 2006-09-06 | Pharmaceutical dosage forms and compositions comprising lecoztan |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20081100L true NO20081100L (en) | 2008-06-03 |
Family
ID=37836444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20081100A NO20081100L (en) | 2005-09-09 | 2008-03-03 | Pharmaceutical dosage forms and compositions |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1928863A2 (en) |
JP (1) | JP2009507850A (en) |
KR (1) | KR20080043855A (en) |
CN (1) | CN101258146A (en) |
AR (1) | AR058033A1 (en) |
AU (1) | AU2006287543A1 (en) |
BR (1) | BRPI0615771A2 (en) |
CA (1) | CA2620491A1 (en) |
CR (1) | CR9800A (en) |
EC (1) | ECSP088236A (en) |
GT (1) | GT200600403A (en) |
IL (1) | IL189827A0 (en) |
NO (1) | NO20081100L (en) |
PE (1) | PE20070334A1 (en) |
RU (1) | RU2008108216A (en) |
TW (1) | TW200800198A (en) |
WO (1) | WO2007030589A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
CN101553217A (en) | 2005-07-06 | 2009-10-07 | 塞普拉科公司 | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment |
JP2012526832A (en) * | 2009-05-13 | 2012-11-01 | スノビオン プハルマセウトイカルス インコーポレイテッド | Composition comprising transnorsertraline and serotonin receptor 1A agonist / antagonist and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL203217B1 (en) * | 2000-09-29 | 2009-09-30 | Solvay Pharm Bv | Ion-strength independent sustained release pharmaceutical formulation |
GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
CN101137648A (en) * | 2005-03-01 | 2008-03-05 | 惠氏公司 | Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin -1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
-
2006
- 2006-09-06 PE PE2006001076A patent/PE20070334A1/en not_active Application Discontinuation
- 2006-09-06 EP EP06790193A patent/EP1928863A2/en not_active Withdrawn
- 2006-09-06 CA CA002620491A patent/CA2620491A1/en not_active Abandoned
- 2006-09-06 WO PCT/US2006/034813 patent/WO2007030589A2/en active Application Filing
- 2006-09-06 KR KR1020087007106A patent/KR20080043855A/en not_active Application Discontinuation
- 2006-09-06 AR ARP060103880A patent/AR058033A1/en unknown
- 2006-09-06 JP JP2008530186A patent/JP2009507850A/en not_active Withdrawn
- 2006-09-06 AU AU2006287543A patent/AU2006287543A1/en not_active Abandoned
- 2006-09-06 CN CNA2006800328607A patent/CN101258146A/en active Pending
- 2006-09-06 TW TW095132852A patent/TW200800198A/en unknown
- 2006-09-06 GT GT200600403A patent/GT200600403A/en unknown
- 2006-09-06 BR BRPI0615771-8A patent/BRPI0615771A2/en not_active Application Discontinuation
- 2006-09-06 RU RU2008108216/14A patent/RU2008108216A/en not_active Application Discontinuation
-
2008
- 2008-02-28 IL IL189827A patent/IL189827A0/en unknown
- 2008-03-03 NO NO20081100A patent/NO20081100L/en not_active Application Discontinuation
- 2008-03-04 EC EC2008008236A patent/ECSP088236A/en unknown
- 2008-03-07 CR CR9800A patent/CR9800A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2620491A1 (en) | 2007-03-15 |
CR9800A (en) | 2008-04-28 |
CN101258146A (en) | 2008-09-03 |
RU2008108216A (en) | 2009-10-20 |
AU2006287543A1 (en) | 2007-03-15 |
BRPI0615771A2 (en) | 2011-05-24 |
PE20070334A1 (en) | 2007-05-08 |
TW200800198A (en) | 2008-01-01 |
EP1928863A2 (en) | 2008-06-11 |
ECSP088236A (en) | 2008-04-28 |
AR058033A1 (en) | 2008-01-23 |
WO2007030589A2 (en) | 2007-03-15 |
KR20080043855A (en) | 2008-05-19 |
JP2009507850A (en) | 2009-02-26 |
WO2007030589A3 (en) | 2007-11-01 |
IL189827A0 (en) | 2008-11-03 |
GT200600403A (en) | 2007-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005092307A3 (en) | Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists | |
NO20080670L (en) | Substituted piperazines as metabotrophic glutamate receptor antagonists | |
NO20090755L (en) | Amino-imidazolones and their use as a drug for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia | |
NO20076638L (en) | New 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor | |
SE0302760D0 (en) | New compounds | |
NO20065060L (en) | Pharmaceutical combinations containing benzoxazine for the treatment of respiratory disorders | |
ATE397605T1 (en) | NEBIVOLOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL | |
MX2009012371A (en) | Metabolites of (thio)carbamoyl-cyclohexane derivatives. | |
NO20082088L (en) | Acetidines as MEK inhibitors for the treatment of proliferative diseases | |
NO20055219L (en) | New connections | |
NO20084049L (en) | Compounds with enhanced ampa receptor and its use in medicine | |
NO20071137L (en) | New piperidine derivatives for the treatment of depression | |
EA200971086A1 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING SCHIZOPHRENIA | |
EA200601194A1 (en) | NEW DERIVATIVES OF BENZOFURANE USED FOR THE PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH 5-HT-RECEPTOR | |
EA200971087A1 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE TREATMENT OF ACUTE MANIA | |
NO20061702L (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist / antagonist | |
NO20080669L (en) | Acetylene piperazines as metabotrophic glutamate receptor antagonists | |
BRPI0411603A (en) | 4- (Aminomethyl) piperidine benzamides as antagonists 5ht4 | |
NO20050903L (en) | New piperazinyl-pyrazinone derivatives for the treatment of 5HT-2A receptor-related disorders | |
NO20081100L (en) | Pharmaceutical dosage forms and compositions | |
ATE495159T1 (en) | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENETE DERIVATIVES | |
NO20074617L (en) | New compounds for the treatment of inflammatory diseases | |
NO20060969L (en) | Benzoxazinone derivative sulfonamide compounds, their preparation and use as drugs | |
NO20080671L (en) | Bicyclic piperazines as metabotrophic glutamate receptor antagonists | |
NO20054495L (en) | Novel aniline derivatives, their preparation and use as pharmaceutical compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |